Cover Image
市場調查報告書

肉毒桿菌中毒症 : 開發中產品分析

Botulism - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 277749
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
肉毒桿菌中毒症 : 開發中產品分析 Botulism - Pipeline Review, H2 2017
出版日期: 2017年07月18日 內容資訊: 英文 45 Pages
簡介

肉毒桿菌中毒是罕見,但致命的嚴重疾病。其原因為肉毒桿菌所產生的毒素。內毒桿菌天然存在於土壤之中。以食物為媒介的肉毒桿菌中毒便是食用了受到肉毒桿菌毒素污染的食品。常見的症狀有複視和視線模糊、眼瞼下垂、口齒不清、吞嚥困難、口渴、肌肉無力等。主要的治療方法為給予抗毒素、加護治療、感染傷口的手術等。

本報告提供肉毒桿菌中毒症治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

肉毒桿菌中毒症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • CytoDel, LLC
  • Hawaii Biotech, Inc.
  • Microbiotix, Inc.
  • Molecular Targeting Technologies, Inc.
  • Nanotherapeutics, Inc.
  • Planet Biotechnology Inc.
  • XOMA Corporation

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9549IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Botulism - Pipeline Review, H2 2017, provides an overview of the Botulism (Infectious Disease) pipeline landscape.

Botulism is a rare but serious illness. The cause is a toxin (poison) made by a bacterium called Clostridium botulinum. It occurs naturally in soil. Food borne botulism comes from eating foods contaminated with the toxin. Symptoms include double or blurred vision, drooping eyelids, slurred speech, difficulty swallowing, dry mouth, and muscle weakness. Treatment may include antitoxins, intensive medical care, or surgery of infected wounds.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Botulism - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Botulism (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Botulism (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Botulism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 6 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Botulism (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Botulism (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Botulism (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Botulism (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Botulism (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Botulism (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Botulism (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Botulism (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Botulism - Overview
    • Botulism - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Botulism - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Botulism - Companies Involved in Therapeutics Development
    • CytoDel LLC
    • Hawaii Biotech Inc
    • Medy-Tox Inc
    • Microbiotix Inc
    • Nanotherapeutics Inc
    • XOMA Corp
  • Botulism - Drug Profiles
    • BoNT/A HcR4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • botulism [serotype C] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • botulism [serotypes A, B, C, D, E] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • botulism [serotypes A, B, E] (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Ctyo-111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Botulinum Neurotoxin Type A for Botulism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Botulinum Toxin for Botulism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NTM-1634 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSX-400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSX-400 Backups - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polyclonal Antibody to Inhibit Botulinum Toxin for Botulism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptides to Inhibit Botulinum Toxin for Botulism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Botulism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit BoNT/A LC for Botulism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Botulinum Neurotoxin Type A for Botulism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XOMA-3AB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XOMA-3BB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Botulism - Dormant Projects
  • Botulism - Discontinued Products
  • Botulism - Product Development Milestones
    • Featured News & Press Releases
      • May 03, 2011: XOMA 3AB, New Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase I Clinical Testing
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Botulism, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Botulism - Pipeline by CytoDel LLC, H2 2017
  • Botulism - Pipeline by Hawaii Biotech Inc, H2 2017
  • Botulism - Pipeline by Medy-Tox Inc, H2 2017
  • Botulism - Pipeline by Microbiotix Inc, H2 2017
  • Botulism - Pipeline by Nanotherapeutics Inc, H2 2017
  • Botulism - Pipeline by XOMA Corp, H2 2017
  • Botulism - Dormant Projects, H2 2017
  • Botulism - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Botulism, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top